NetworkNewsBreaks

ThursdayApr 13, 2017 12:59 pm

NetworkNewsBreaks – Relmada Therapeutics, Inc.’s (RLMD) d-Methadone Receives Fast Track Designation by FDA; Shares Rise

Relmada Therapeutics’ (OTCQB: RLMD) shares are up 20% mid-day after the company said that it has received Fast Track designation for d-Methadone from the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder. This designation offers many advantages, including more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of…

Continue Reading

ThursdayApr 13, 2017 11:57 am

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Receives ‘Hold’ Rating, Reduced PT at Aegis Capital

Aegis Capital has issued a ‘Hold’ rating and a lowered price target of $2 on shares of Intellipharmaceutics International (NASDAQ: IPCI). The news follows recent patent litigation from Purdue Pharma against Intellipharmaceutics regarding the New Drug Application (“NDA”) filing for its Rexista™ product candidate. The FDA is stayed for 30 months from granting final approval to the company’s Rexista™ as a result of these legal proceedings, unless a final declaration of the courts is entered that the patents are either invalid or are not infringed, or the matter is otherwise settled among the parties. The analyst noted the patent suit,…

Continue Reading

ThursdayApr 13, 2017 11:53 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $25 PT on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE). The report follows the unexpected delay of the company’s CTP-543 phase 2a trial for alopecia areata. The delay of one quarter was caused by the tablet being unable to meet release criteria regarding appearance. The analyst noted this delay as insignificant and reiterated the ‘Buy’ rating. For more information visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet…

Continue Reading

ThursdayApr 13, 2017 11:51 am

NetworkNewsBreaks – SeeThruEquity Issues Updated Coverage on GEE Group, Inc. (NYSE: JOB)

SeeThruEquity has issued an update on shares of GEE Group’s (NYSE: JOB) stock following recent first quarter 2017 financial results, in which the company reported revenues of $22 million, compared to $17.6 million in the first quarter of 2016. GEE Group also recently acquired SNI Companies, a private staffing company with over $100 million in annual revenue. The analyst cited this acquisition as fuel to accelerate the company’s penetration into professional staffing and generate cash flow. For more information visit www.geegroup.com About GEE Group Inc. GEE Group Inc. is a provider of specialized staffing solutions and is the successor to…

Continue Reading

WednesdayApr 12, 2017 12:26 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 12, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: AKDS 15.45% – News: Signs beta site agreement with Yuma Way for Arktic™ Smart Building solution MSDI 8.04% – News: Enters distribution agreement with Ingram Entertainment KSHB 5.38% – News: Posts Q2 2017 results RNVA 5.30% – News: Posts FY 2016 results NURO 5.26% – News: Reporting Q1 2017 results, hosting conference call April 20 PTLF 5.02% – News: Releases overview of holistic pet health practices JNP 4.94% – News: Publishes open letter urging…

Continue Reading

WednesdayApr 12, 2017 12:23 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Medical Transcription Billing, Corp. (NASDAQ: MTBC)

SeeThruEquity recently issued an update on Medical Transcription Billing (NASDAQ: MTBC). The news follows the company’s report of financial results for the quarter and year ended December 31, 2016. MTBC reported full year revenues in 2016 of $24.5 million, a 6% increase over $23.1 million in 2015. The company also reported 65% year-over-year growth in the fourth quarter of 2016 with revenues of $8.8 million. The analyst noted this in the report and attributes the growth primarily to the company’s recent acquisition of MediGain LLC and its subsidiary, Millennium Practice Management, LLC. According to company management, the acquisition of MediGain…

Continue Reading

WednesdayApr 12, 2017 12:06 pm

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Schedules End of Phase 2 FDA Meeting, Initiates Phase 3 Development

Ritter Pharmaceuticals (NASDAQ: RTTR) shares are up 15% after the company said that the U.S. Food and Drug Administration (FDA) has agreed to an end of phase 2 meeting. The meeting is expected to take place in the third quarter of 2017 to discuss the results of Ritter’s recently completed phase 2b/3 trial, which demonstrated numerous positive topline results. A full analysis of the data is currently underway. The company also plans to discuss phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. "Based on the topline results of…

Continue Reading

WednesdayApr 12, 2017 10:39 am

NetworkNewsBreaks – Grey Cloak Tech, Inc. (GRCK) Completes Acquisition of ShareRails

Grey Cloak Tech, Inc. (OTC: GRCK) this morning announced the completion of its acquisition of ShareRails, a provider of online-to-offline (O2O) e-commerce services that is currently valued at more than $6.4 million by Excel Management Systems. “This is a great opportunity for Grey Cloak Tech,” Fred Covely, CEO of Grey Cloak Tech, stated in the news release. “Our entire management team spent a week in Hong Kong last month with the ShareRails development team. We met with the platform's existing clients, as well as developed new relationships, and recognize that the online-to-offline business opportunities are substantial in the southeast region…

Continue Reading

TuesdayApr 11, 2017 1:17 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 11, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: WINT 18.95% – News: Reports completion of final interim safety review of AEROSURF® by Data Safety Monitoring Board RMGN 18.06% – News: Secures contract for second major supply chain customer roll-out in 2017 DTRM 12.05% – News: Determine cloud platform selected by Orion Corporation SNYR 11.11% – News: Launches The Synergy Effect AMMA 10.69% – News: Two alumni win at UFC 210 WTER 7.90% – News: Appoints new members to advisory board ARQL 5.45%…

Continue Reading

TuesdayApr 11, 2017 1:16 pm

NetworkNewsBreaks – Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) Meets Phase 1 Portion of Intratumoral IMO-2125 Combination Trial, Begins Enrolling Phase 2 Trial

Idera Pharmaceuticals (NASDAQ: IDRA) this morning announced the successful completion of the phase 1 portion of the ongoing phase 1/2 clinical trial of intratumoral IMO-2125 for the treatment of anti-PD-1 refractory metastatic melanoma. Enrollment has commenced for the phase 2 portion of the trial, and Idera expects to have overall response rate (ORR) data available in the first quarter of 2018. “There is a very clear unmet medical need for those patients for whom current checkpoint inhibitor therapies are not providing adequate solutions. We are incredibly focused on advancing this program as rapidly as possible for these patients, and we…

Continue Reading